perations, net income and income per diluted share of the company excluding unusual items. Management uses and presents adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measures because management believes that such adjustments facilitate an understanding of the financial impact of unusual items on the company's short- and long-term financial trends. Management also uses adjusted non-GAAP items to forecast and to evaluate the operational performance of the company, as well as to compare results of current periods to prior periods on a consistent basis. Adjusted earnings before interest, tax, depreciation and amortization ("EBITDA") measures the adjusted non-GAAP income from operations of the company and excludes the aforementioned items, as well as non-cash equity compensation and other income (expense) items.
Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
Please refer to the attached reconciliations between GAAP and non-GAAP financial measures.
First Quarter Results Webcast and Conference Call InstructionsCyberonics will host a conference call today, August 22, 2013, beginning at 8:00 a.m. Central Time (9:00 a.m. Eastern Time) to review its results of operations for the fiscal year 2014 first quarter, followed by a question and answer session.
The conference call will be available to interested parties through a live audio webcast in the Investor Relations section of Cyberonics' corporate website at http://www.cyberonics.com. To listen to the conference call live by telephone, dial 877-638-4557 (if dialing from wiPage: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. SPO Reports Results for Second Quarter 20132
. Global IVIG Market Report 2013 Edition Research at MarketReportsOnline.com3
. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights4
. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com5
. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update6
. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results7
. Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update8
. Dyadic International Reports Second Quarter 2013 Financial Results9
. Microbes Market and Microbial Products Reviewed in New Research Report at ReportsnReports.com10
. Discovery Labs Reports Second Quarter 2013 Financial Results11
. Global Crop Protection Chemicals Market Till 2016 - Worldwide Research Report, Industry Share, Size, Trends, Analysis, Growth and Forecast 2012-2016: MarketResearchReports